PARP1 and neoplasm: Preclinical models have shown that PARP inhibition enhances immune checkpoint blockade (ICB) efficacy by promoting neoantigen release, activating the cGAS–STING–IFN axis, and upregulating PD-L1 expression, thereby creating a more immunostimulatory tumor microenvironment (32, 33).